"Cardiovascular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
| Descriptor ID |
D002317
|
| MeSH Number(s) |
D27.505.954.411
|
| Concept/Terms |
Cardiovascular Agents- Cardiovascular Agents
- Agents, Cardiovascular
- Cardiovascular Drugs
- Drugs, Cardiovascular
|
Below are MeSH descriptors whose meaning is more general than "Cardiovascular Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiovascular Agents".
This graph shows the total number of publications written about "Cardiovascular Agents" by people in this website by year, and whether "Cardiovascular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 3 | 0 | 3 |
| 2008 | 3 | 0 | 3 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 3 | 5 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 4 | 1 | 5 |
| 2015 | 1 | 0 | 1 |
| 2016 | 4 | 0 | 4 |
| 2017 | 4 | 1 | 5 |
| 2018 | 4 | 0 | 4 |
| 2019 | 3 | 0 | 3 |
| 2020 | 4 | 2 | 6 |
| 2021 | 0 | 2 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiovascular Agents" by people in Profiles.
-
Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure. Am J Cardiovasc Drugs. 2024 Jul; 24(4):481-504.
-
Contemporary pharmacological treatment and management of heart failure. Nat Rev Cardiol. 2024 08; 21(8):545-555.
-
When Is It Appropriate to Publish a Meta-Analysis in Cardiovascular Drugs and Therapy? Cardiovasc Drugs Ther. 2023 06; 37(3):599-601.
-
More reassuring safety data regarding paclitaxel-eluting technologies in lower extremity revascularization. J Vasc Surg. 2022 02; 75(2):608-609.
-
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. Hypertension. 2022 04; 79(4):827-835.
-
New evidence and innovations for carotid disease and popliteal artery aneurysm management. J Vasc Surg. 2022 01; 75(1S):1S.
-
Characteristics and Outcomes of Early Recurrent Myocardial Infarction After Acute Myocardial Infarction. J Am Heart Assoc. 2021 08 17; 10(16):e019270.
-
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations. Am Heart J. 2021 11; 241:38-49.
-
2021 The American Association for Thoracic Surgery expert consensus document: Surgical treatment of acute type A aortic dissection. J Thorac Cardiovasc Surg. 2021 09; 162(3):735-758.e2.
-
The plague of unexpected drug recalls and the pandemic of falsified medications in cardiovascular medicine as a threat to patient safety and global public health: A brief review. Cardiol J. 2022; 29(1):133-139.